An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma — Stella

Home/Gastroesophageal Junction (GEJ) Adenocarcinoma/

View on ClinicalTrials.gov

Recruiting

Back to Gastroesophageal Junction (GEJ) Adenocarcinoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

Japan

National Cancer Center Hospital East, Kashiwa, Chiba

Key details

Phase

Safety & dosing

Sponsor

National Cancer Center Hospital East

Collaborators

Merck Sharp & Dohme LLC

Enrollment target

~26 participants

Started

July 2025

Primary completion

June 2030

Age range

18 Years and older

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.